利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

26 条记录 (耗时 0.035 秒)

    Determining the capability of a test compound to affect solid tumor stem cells
    5.
    发明授权
    Determining the capability of a test compound to affect solid tumor stem cells 有权
    测定化合物影响实体瘤干细胞的能力

    公开(公告)号：US08420885B2

    公开(公告)日：2013-04-16

    申请号：US13241701

    申请日：2011-09-23

    申请人： Michael F. Clarke ,  Scott J. Dylla ,  Sanjeev Satyal

    发明人： Michael F. Clarke ,  Scott J. Dylla ,  Sanjeev Satyal

    IPC分类号： C12Q1/00 ,  G01N33/50 ,  C07K14/705 ,  C07K16/18 ,  A61K39/00

    CPC分类号： G01N33/5011 ,  A01K67/0271 ,  A61K2039/505 ,  A61K2039/5152 ,  A61K2039/5158 ,  B82Y30/00 ,  C12N5/0695 ,  C12N2501/42 ,  C12N2503/00 ,  C12N2503/02 ,  G01N33/5088 ,  G01N33/57492

    摘要： A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumor cells in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.

    摘要翻译： 建立的实体瘤内的一小部分细胞具有干细胞的特性。 这些实体肿瘤干细胞产生更多的肿瘤干细胞和肿瘤中大部分已经失去广泛增殖能力的细胞和产生新肿瘤的能力。 因此，实体肿瘤异质性反映了由固体肿瘤干细胞产生的肿瘤细胞后代的存在。 我们已经开发了异种移植模型，其中我们已经能够通过在严重免疫缺陷小鼠的乳腺中注射肿瘤细胞从原发性肿瘤建立肿瘤。 这些异种移植物测定使我们能够进行生物学和分子测定来表征克隆型实体瘤干细胞。 我们还发现证据强烈地暗示Notch途径，特别是Notch 4，作为致癌过程的中心途径。

    Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
    6.
    发明授权
    Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth 有权
    用于抑制Wnt依赖性实体瘤细胞生长的组合物和方法

    公开(公告)号：US07723477B2

    公开(公告)日：2010-05-25

    申请号：US11589931

    申请日：2006-10-31

    申请人： Austin Gurney ,  John Lewicki ,  Sanjeev Satyal ,  Timothy Hoey

    发明人： Austin Gurney ,  John Lewicki ,  Sanjeev Satyal ,  Timothy Hoey

    IPC分类号： A61K38/00 ,  C07K1/00 ,  C07K14/00 ,  C07K17/00 ,  C07K2/00 ,  C07K4/00 ,  C07K5/00 ,  C07K7/00 ,  C07K16/00

    CPC分类号： C07K14/705 ,  A61K38/00 ,  A61K45/06 ,  A61K2039/505 ,  C07K14/723 ,  C07K16/00 ,  C07K16/18 ,  C07K16/28 ,  C07K2319/30 ,  C07K2319/33 ,  G01N33/57423 ,  G01N33/57492

    摘要： The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.

    摘要翻译： 本发明涉及用于表征，诊断和治疗癌症的组合物和方法。 特别地，本发明提供了用于癌症的诊断，表征，预后和治疗以及特异性靶向癌症干细胞的方法和方法。 本发明提供了包含抑制肿瘤细胞生长的人FZD受体的细胞外结构域的可溶性FZD受体。 本发明还提供一种可溶性受体，其包含结合人FZD受体的配体的人FZD受体的Fri结构域，并且所述可溶性受体能够抑制肿瘤生长。 本发明还提供一种治疗癌症的方法，其包括以有效抑制肿瘤生长的量给予包含例如人FZD受体的细胞外结构域或人FZD受体的Fri结构域的可溶性FZD受体。